1. Scrip
  2. >>Business
  3. >>Deals

Merck Acquires Much Needed Diversification With $10.8bn Prometheus Buy

$200 Per Share Buyout Is 75% Premium

 
• By Mandy Jackson

Merck will reduce its dependence on oncology and expand in immunology, adding a Phase III-ready TL1A inhibitor for IBD that could reach the market a few years ahead of losing exclusivity for Keytruda.

Pain in human intestines, bowel concept
PRA023 will move into Phase III in ulcerative colitis and Crohn's disease in late 2023 or early 2024 • Source: Shutterstock

Merck & Co., Inc. has agreed to pay $10.8bn for Prometheus Biosciences, Inc. and its Phase III-ready TNF-like ligand 1A (TL1A) inhibitor PRA023, which showed promising efficacy in inflammatory bowel disease (IBD) indications late last year. The deal gives Merck a potential blockbuster immunology asset that may help it make up for some of the revenue it will lose at the end of this decade after its top-selling product Keytruda (pembrolizumab) loses exclusivity.

Analysts cheered the deal, announced 16 April, despite the high price tag, as a means of diversifying the big pharma’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 
• By Alaric DeArment

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 
• By Sushmita Panda

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By Joseph Haas

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

More from Business

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.

Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates

 
• By Mandy Jackson

Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By Joseph Haas

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.